FDA panel recommends mRNA flu vaccine for older adults
The Hill
—
A first-of-its-kind flu shot is a step closer to being available to the public after a Food and Drug Administration (FDA) advisory panel voted Thursday to recommend Moderna’s mRNA-based vaccine for approval.
The FDA’s independent vaccine advisors voted unanimously 9-0 that the benefits outweigh the risks for Moderna’s mFlusiva shot in people ages 50 to 64 as well as 65 and older.
Moderna is seeking…
FDA Panel Backs Moderna mRNA Flu Shot
- FDA panel recommends Moderna’s mRNA flu shot for older adults NBC News —
- FDA advisors unanimously vote to approve Moderna's mRNA after agency drama Ars Technica —
- Key FDA committee unanimously recommends its first vaccine since 2023 NPR —
- FDA panel backs first-of-its-kind flu vaccine using mRNA technology PBS —